M. A. Winning

Suggest Changes
Learn More
A Phase I trial has been conducted in patients with refractory/relapsed acute leukemia in which escalating doses of the protein kinase C (PKC) activator and down-regulator bryostatin 1 (NSC399555),(More)
  • 1